Recent Posts


Screening Works!

February 20th, 2020|Hot Topics, News|

By James L. Mulshine, MD, Scientific Leadership Board, GO2 Foundation for Lung Cancer, Professor, Internal Medicine, Rush University We had another home run for the lung cancer community.  On February 6, 2020 the New England Journal of Medicine published the long awaited results of the NELSON Trial (the Dutch-Belgium [...]

Drug Resistance and Newly-Funded Research

February 13th, 2020|Hot Topics, News|

by Amy C. Moore, PhD, Director, Science & Research, GO2 Foundation for Lung Cancer Patients with lung cancer face the challenge of drug resistance, while researchers focus on extending treatment duration. In collaboration with the patient group ALK Positive, we have awarded a new research collaboration grant dedicated to [...]

$500,000 Research Grant to Combat Cancer Treatment Resistance Awarded by ALK Positive and GO2 Foundation

February 6th, 2020|Hot Topics, News, Press Releases|

SAN CARLOS, Calif. and WASHINGTON, Feb. 6, 2020 /PRNewswire/ -- ALK Positive (a patient-led group of 1,900+ lung cancer patients and caregivers in 50+ countries) and GO2 Foundation for Lung Cancer (a global lung cancer advocacy and education organization) are awarding a two-year, $500,000 Research Collaboration Grant to two renowned lung cancer researchers dedicated to overcoming treatment resistance. This grant [...]

Team Captains Baking for the Cause

February 6th, 2020|Community Engagement, Hot Topics|

Laura and Krista at their Cupcake Baking Event Meet Laura Rodriguez, a mother, survivor, and champion for the lung cancer community. When Laura was diagnosed with stage IV ALK+ lung cancer in 2012, her world forever changed. Today, she shows no evidence of disease (NED) thanks to biomarker testing and targeted therapy treatments. Laura and her [...]

The Power of the Patient Voice

January 30th, 2020|Hot Topics|

Patient-reported outcomes (PROs) have been used in cancer clinical trials for more than 20 years. Along with clinical evidence, healthcare decision-makers use PROs to guide both individual patient choice and shared decision making. Unfortunately, the patient voice is often lost in clinical trial development because of inadequate or poor [...]

Lung Cancer Research: How You Can Make a Difference

January 23rd, 2020|Hot Topics, News|

Did you know that you can help change the future of lung cancer? One of GO2 Foundation’s core pillars is to advance world-class, patient-centered, academic and community-based research that spans the continuum of care. To achieve this we, along with our partners and collaborators, offer our community many opportunities [...]

Advances in Lung Cancer Treatment Drops U.S. Cancer Deaths

January 9th, 2020|Hot Topics, News|

GO2 Foundation for Lung Cancer points to targeted treatments and early screenings SAN CARLOS, Calif. and WASHINGTON, Jan. 8, 2020 /PRNewswire/ -- Today's report concerning improvements in cancer mortality is welcomed news. The recently released Cancer Statistics 2020 report shows that the decline in lung cancer deaths is driving the decrease in mortality rates for cancer [...]

Year-end Progress for the Lung Cancer Community: Federal Research Funding & the Women and Lung Cancer Research and Preventive Services Act

December 21st, 2019|Hot Topics, News|

For many weeks, our community has been awaiting passage of the Fiscal Year 2020 (FY20) federal budget, which funds the Lung Cancer Research Program. This week, just days before the budget continuing resolution expired, the House and Senate released the long-awaited conferenced agreement that has been signed by the [...]

Stories That Inspire

December 19th, 2019|Hot Topics, Stories of Hope|

From advancements in research and progress on Capitol Hill, to working directly with survivors and families, 2019 has been a monumental inaugural year for us at GO2 Foundation. At the heart of everything we do is our patient community; you continue to inspire and motivate us every day. Some [...]

FDA Approves Tecentriq Plus Chemotherapy as a First-Line Treatment for Metastatic NSCLC

December 5th, 2019|Hot Topics, News|

On December 3, 2019, the U.S. Food and Drug Administration approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) as a first treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK changes. This approval is based on the [...]

GO2 Foundation for Lung Cancer Announces Young Innovators Team Award Recipients

December 3rd, 2019|Hot Topics, News, Press Releases|

SAN CARLOS, Calif., Dec. 3, 2019 -- GO2 Foundation for Lung Cancer announced the recipients of the 2019 Young Innovators Team Awards (YITA) today. Two teams of researchers received grants totaling $500,000 for their work developing novel strategies to treat KRAS-mutant non-small cell lung cancer (NSCLC) and examining the impact of age on development, progression, [...]

The Power of Partnerships—EGFR-Mutant Lung Cancer

November 21st, 2019|Hot Topics|

We fight lung cancer together. That’s a lesson we’ve learned and put into action. Amy C. Moore, PhD, our Director of Science & Research, recently published an article in the International Association for the Study of Lung Cancer online news about the importance of building research models utilizing partnerships [...]

It’s Time to Shine!

October 31st, 2019|Community Engagement, Hot Topics|

Can you believe Lung Cancer Awareness Month kicks off tomorrow? Our Shine a Light on Lung Cancer events make it easy for you to celebrate and remember survivors, caregivers and all individuals who have been impacted by the disease. What can you expect at a Shine a Light event? [...]